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Chronic Thromboembolic Pulmonary 
Hypertension and Antiphospholipid Syndrome 
with Immune Thrombocytopenia: A Case Report
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 Patient: Male, 23
 Final Diagnosis: Antiphospholipid syndrome
 Symptoms: Dyspnea
 Medication: —
 Clinical Procedure: Right heart catheterization
 Specialty: General and Internal Medicine
 Objective: Rare disease
 Background: Antiphospholipid syndrome is an autoimmune disorder characterized by a hypercoagulable state associated 
with circulating antiphospholipid antibodies. The presence of antiphospholipid antibodies can result in a variety 
of clinical symptoms, such as thrombocytopenia, stillbirth, endocardial pathologies, and recurrent pulmonary 
embolism.
 Case Report: We present the case of a 23-year-old man with antiphospholipid syndrome and chronic thromboembolic pul-
monary hypertension who developed severe thrombocytopenia. The patient died from right heart failure before 
the thrombocytopenia could be managed, preventing performance of a pulmonary endarterectomy procedure.
 Conclusions: Managing platelet counts in patients with antiphospholipid syndrome prior to major surgery is very problematic, 
and requires similar treatment strategy as in patients with immune thrombocytic thrombocytopenia. Platelet 
transfusions may further decrease platelet count, as it can trigger formation of new antibodies.
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 Abbreviations: aPL – antiphospholipid antibodies; APS – antiphospholipid syndrome; CTEPH – chronic thromboembolic 
pulmonary hypertension; ITP – immune thrombocytopenic purpura; PEA – pulmonary thromboendarter-
ectomy; PAWP – pulmonary artery wedge pressure
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Background
Antiphospholipid syndrome (APS) is an autoimmune disorder 
characterized by a hypercoagulable state associated with cir-
culating antiphospholipid antibodies (aPL) [1]. The presence of 
aPL can result in variety of clinical symptoms, such as throm-
bocytopenia, stillbirth, endocardial pathologies, and recurrent 
pulmonary embolism. Thrombocytopenia can be present in as 
many as 23.4% of APS cases [2].
Antiphospholipid antibodies are commonly found in patients 
with immune thrombocytopenic purpura (ITP), but the clinical 
significance is still controversial [3].
Mechanisms of thrombocytopenia associated with APS can vary. 
It can occur due to immune-mediated clearance of platelets, 
as seen in ITP patients, or less frequently as a consequence 
of interaction between aPL and platelets triggering aggrega-
tion and thrombosis [4].
Due to similar pathogenetic mechanisms, patients with both 
aPL and thrombocytopenia are treated as ITP. The preferred 
first-line treatment is oral prednisone 1–2 mg/kg/day, but it 
is possible to use higher and lower doses of prednisone or 
methylprednisolone. Patients who are unresponsive or in-
tolerant to glucocorticoids can be treated with immunosup-
pressive drugs such as azathioprine and cyclophosphamide. 
Intravenous immunoglobulin is used in patients with life-
threatening bleeding or to rapidly increase platelet counts. 
Rituximab, which has been used off-label in ITP patients, has 
also proven itself to be effective in APS-associated thrombo-
cytopenia [5]. Splenectomy should be postponed for as long 
as possible, and done only for patients who are unresponsive 
to glucocorticoids and immunosuppressants.
Antiphospholipid syndrome may result in various clinical syn-
dromes, and CTEPH is one of them [6]. Chronic thromboembolic 
pulmonary hypertension is classified as group 4 pulmonary 
hypertension caused by chronic thromboembolic obstruction 
and clinically manifests as exercise intolerance, fatigue, and 
progressive dyspnea on exertion [7]. Chronic thromboembolic 
pulmonary hypertension stands out from other types of pul-
monary hypertension because it is curable by pulmonary end-
arterectomy (PEA) [8]. Pulmonary endarterectomy requires a 
median sternotomy, cardiopulmonary bypass, and periods of 
deep hypothermic circulatory arrest. Twenty-minute periods 
of hypothermic circulatory arrest ensures a bloodless surgical 
field. It is done in expert centers only, as the procedure is very 
complex. Studies have shown that quality of life and life ex-
pectancy increase for a majority of patients after PEA [9,10].
Case Report
A 23-year-old man was referred to Pauls Stradins Clinical 
University Hospital in January 2015 with complaints of progres-
sive dyspnea on exertion (New York Heart Association func-
tional class III). He had been diagnosed with APS in October 
2007 (Table 1) when he was hospitalized due to a pulmonary 
embolism, and was on therapy with vitamin K antagonist and 
regular INR monitoring since. The patient had had another pul-
monary embolism in 2012. In concomitant therapy, the patient 
received bisoprolol 10 mg PO daily, torsemide 10 mg PO daily, 
and spironolactone 50 mg PO daily.
Laboratory results revealed thrombocytopenia with a platelet 
count of 89×109/L and INR of 2.0. The patient’s liver enzymes 
were slightly elevated – ALT was 68 U/L and AST 46 U/L. There 
were no signs of impaired kidney function. Echocardiography 
revealed significant right heart dilatation and overload with 
tricuspid valve regurgitation (grade II–III), mild pericardial ef-
fusion, and severe pulmonary hypertension (right ventricular 
systolic pressure of 70 mmHg) with a left ventricular ejection 
fraction of 45%. Estimated central venous pressure (CVP) was 
19 mmHg.
Computed tomography angiography of the chest showed chronic 
bilateral thromboemboli of pulmonary artery branches, and 
fresh thromboemboli of the right pulmonary artery, including 
total occlusion of the right upper-lobe artery.
On January 5th, 2015, the patient underwent right heart cath-
eterization, which confirmed the diagnosis of CTEPH (Table 2).
The patient was started on ambrisentan 5 mg PO on January 6th, 
2015. Ambrisentan was chosen instead of riociguat because it is 
state-compensated in Latvia. A team of pulmonary hypertension 
specialists from PSCUH and Vienna General Hospital decided 
that the patient should undergo evaluation regarding eligibility 
for PEA. Therefore, the patient was admitted to Vienna General 
Hospital on May 2015. On admission, pitting peripheral edema 






IgG phospholipid antibodies, 
U/ml (RI <15 U/ml)
63 67
IgM phospholipid antibodies, 
U/ml (RI <15 U/ml)
3.5 5.1
IgG, Anti-b2 GPI antibodies, 
U/ml (RI <15 U/ml)
84 73
Table 1. Antiphospholipid syndrome antibodies.
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had severe dyspnea. Central venous pressure was estimated 
at 21 mmHg. The patient’s platelet count was 43×109/L and he 
was given 1 bag of platelets on May 16th and started on enoxa-
parin 40 mg SC. Anti-nuclear antibodies, anti-nuclear neutrophil 
antibodies, rheumatoid factor, and anti-double-stranded DNA 
antibodies were negative. The patient was prescribed 75 mg of 
prednisone PO daily on May 18th. Because the platelet count 
further deteriorated (24×109/L), heparin-induced thrombocy-
topenia was suspected, but antibodies against platelet fac-
tor 4 were negative. Treatment with eltrombopag 50 mg PO 
daily was started on May 22nd, 2015. Eltrombopag is a small-
molecule agonist of the c-mpl receptor, a physiological target 
of thrombopoietin, and is used to treat ITP that is unrespon-
sive to corticosteroids, immunoglobulins, or splenectomy [11].
Platelet count on June 3rd, 2015 was 2×109/L. Due to the increas-
ing inability to oxygenate, the patient was intubated. The pa-
tient died on the following day from severe right-heart failure.
An autopsy was done shortly after death and the pathology 
report confirmed right ventricular hypertrophy with cor pul-
monale. There was complete thrombotic occlusion of the right 
pulmonary artery and several occlusions in peripheral pulmo-
nary artery segments in the left lung. Bone marrow was nor-
mocellular. Liver congestion II and pulmonary congestion with 
edema were present.
Discussion
The management of the patient was highly complicated due 
to numerous comorbidities – CTEPH, APS causing progressive 
thrombocytopenia, and possible concomitant and previously un-
diagnosed left-heart disease with congestion in lungs and liver. 
In cases like this, it is hard to outline any treatment strategy 
as the correct or the best one.
The possible dysfunction of the left ventricle is suggested by 
the decreased ejection fraction, notably increased pulmonary 
artery wedge pressure (PCWP) of 23 mmHg (pre-capillary pul-
monary hypertension is characterized by PCWP of £15 mmHg), 
and the autopsy results [7].
The recommended INR for patients with APS is 2.0–3.0 [12]. 
However, for patients with CTEPH, it should be in the target 
range of 2.5–3.5, with preferably higher INR in cases of under-
lying thrombophilia such as APS [7]. This suggests that the an-
ticoagulation therapy was most likely not adequate from 2007 
to 2015, when the patient received a vitamin K antagonist.
Pulmonary endarterectomy is the treatment of choice for op-
erable CTEPH [8]. Pre-operative risk stratification is essential, 
with hemorrhagic risk being one of the top priorities. In our 
case, the patient’s platelet count before the planned surgery 
was 43×109/L, which is below the recommended threshold for 
major surgery of 50×109/L [13]. Usually, patients with APS have 
mild thrombocytopenia (>50×109/L) that does not require any 
special management [5]. There are reports on splenectomy to 
manage thrombocytopenia in patients with APS in cases where 
other treatment fails to control platelet counts [14–16]. In this 
case, splenectomy would be a questionable choice as the pa-
tient had severe heart failure and was in a critical state.
Because thrombocytopenia in APS patients is similar to ITP, the 
treatment remains the same, with glucocorticoids strongly recom-
mended as first-line treatment [5,17]. Patients initially unrespon-
sive to glucocorticoids should be receiving immunosuppressive 
drugs such as azathioprine or cyclophosphamide [1] or immuno-
modulating agents and intravenous immunoglobulins [5,17,18].
The use of eltrombopag has proven to be highly effective in 
patients with ITP. Up to 88.8% of the patients achieve platelet 
response [19].
Although antiplatelet antibodies were not determined in this 
case, the available data showing negative antibodies against 
platelet factor 4 and normocellular bone marrow and no other 
relevant findings in autopsy, rule out other possible causes of 
thrombocytopenia in APS, such as heparin-induced thrombo-
cytopenia, thrombotic microangiopathy, bone marrow necrosis, 
and hemophagocytic syndrome [5].
It is debatable whether other treatment options, such as im-
munosuppressants, immunoglobulins, or even splenectomy, 
would have changed the outcome of this case, but it has high 
educational value and raises awareness of various issues en-









PVR, Wood units 10
PAWP, mmHg 23
Table 2. Right-heart catheterization.
CI – cardiac index; CO – cardiac output; mPAP – mean pulmonary 
artery pressure; PADP – pulmonary arterial diastolic pressure; 
PASP – pulmonary arterial systolic pressure; PAWP – pulmonary 
arterial wedge pressure; PVR – pulmonary vascular resistance.
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Conclusions
Antiphospholipid syndrome presenting with severe thrombocy-
topenia still remains a challenge, which requires an individual 
approach and planned treatment strategy, preceded by thor-
ough patient work-up. All treatment options at hand need to 
be weighed and managed by an experienced, multidisciplinary 
team of pulmonologists, hematologists, and surgeons. Since 
there are no treatment guidelines for thrombocytopenia in APS, 
more studies are needed to understand the pathogenesis, clin-
ical associations, and management of this condition.
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